Brevan Howard Capital Management’s Harmony Biosciences HRMY Stock Holding History

Brevan Howard Capital Management’s Portfolio HRMY Stock Details HRMY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.79M	Buy	49,042 +23,854	+95%	+$752K	0.01%	770
2026 Q1	$706K	Buy	25,188 +19,433	+338%	+$637K	0.01%	1104
2025 Q4	$215K	Sell	5,755 -6,575	-53%	-$216K	﹤0.01%	1541
2025 Q3	$340K	Buy	+12,330	New	+$425K	﹤0.01%	1507
2025 Q2	–	Sell	-28,362	Closed	-$941K	–	1913
2025 Q1	$941K	Sell	28,362 -14,967	-35%	-$537K	0.01%	522
2024 Q4	$1.49M	Buy	+43,329	New	+$1.49M	0.01%	342
2024 Q3	–	Sell	-6,847	Closed	-$207K	–	1270
2024 Q2	$207K	Buy	+6,847	New	+$206K	﹤0.01%	882
2024 Q1	–	Sell	-6,934	Closed	-$224K	–	1142
2023 Q4	$224K	Buy	+6,934	New	+$194K	﹤0.01%	846

Other funds holding HRMY

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Brevan Howard Capital Management's HRMY Position: Q2 2026 in Review

Brevan Howard Capital Management increased its Harmony Biosciences (HRMY) stake by 95% in Q2 2026, buying an estimated $752K and bringing the position to 49,042 shares worth $1.79M. The position accounts for 0.01% of the portfolio, ranked #770.

Brevan Howard Capital Management first reported a position in HRMY in Q4 2023 and has held it in 8 quarters since. 327 funds tracked by Wall St. Rank hold HRMY as of Q2 2026.

Brevan Howard Capital Management held 49,042 shares of Harmony Biosciences worth $1.79M as of Q2 2026.
Brevan Howard Capital Management bought 23,854 Harmony Biosciences shares in Q2 2026, an estimated $752K.
Harmony Biosciences made up 0.01% of Brevan Howard Capital Management's portfolio in Q2 2026, its #770 holding.
Brevan Howard Capital Management first reported a position in Harmony Biosciences in Q4 2023 and has held it in 8 quarters since.
327 funds tracked by Wall St. Rank held Harmony Biosciences as of Q2 2026.

Based on Brevan Howard Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.